ImmunoPET Imaging of Nectin4 Expression in Gastric and Bladder Cancer Using [Cu]Cu-NOTA-Padcev.

Nectin4 is a tumor-associated antigen that is highly expressed in various solid tumors and is associated with tumor progression and poor prognosis. We performed an ImmunoPET imaging study to assess Nectin4 expression in gastric and bladder cancer models utilizing [Cu]Cu-NOTA-Padcev. ImmunoPET imaging confirmed significant tumor uptake at 48 h in NCI-N87 (13.83 ± 1.80% ID/g) and HT-1376 (22.97 ± 2.67% ID/g) models, which was significantly higher than in HGC-27 (5.93 ± 0.15% ID/g, = 0.0163) and UM-UC-3 (5.40 ± 0.69% ID/g, = 0.0051) models. Co-injection of [Cu]Cu-NOTA-Padcev with 2 mg of unlabeled Padcev significantly decreased tumor uptake in NCI-N87 (5.53 ± 0.59% ID/g, = 0.0097) and HT-1376 (4.97 ± 0.68% ID/g, = 0.0049), indicating receptor-specific binding. Fluorescence imaging consistently showed significantly greater tumor accumulation in the IRDye 800CW-Padcev group than in the blocking group for both the NCI-N87 model (64.05 ± 8.97 × 10 vs 10.12 ± 1.83 × 10 at 168 h for the NCI-N87 model, = 0.0072) and the HT-1376 model (99.48 ± 13.61 × 10 vs 10.12 ± 1.83 × 10 at 168 h for the HT-1376 model, = 0.0068). [Cu]Cu-NOTA-Padcev ImmunoPET imaging demonstrated specific, rapid, and prolonged accumulation in Nectin4-high tumors in both gastric and bladder cancer models.